Fulcrum ends covid med trial

 After careful consideration, Fulcrum is discontinuing LOSVID, a Phase 3 trial with losmapimod for hospitalized subjects with COVID-19, due to significant changes in the COVID-19 treatment paradigm, including new therapeutic options and emerging vaccines.

• The company has decided to redeploy its resources to other clinical programs and discovery efforts, with a continued focus on rare diseases.
• Losmapimod was generally well tolerated in LOSVID, and an independent data safety monitoring board did not identify any safety concerns related to losmapimod.

https://www.globenewswire.com/news-release/2021/03/04/2186976/0/en/Fulcrum-Therapeutics-Reports-Recent-Business-Highlights-and-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html